Nektar Therapeutics | NKTR - Operating Expenses


Nektar Therapeutics reported $40.9M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Cara Therapeutics USD 5.94M 983K Sep/2025
Cipla INR 59.27B 1.71B Mar/2026
Dr.Reddys Laboratories INR 74.58B 977M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Exelixis USD 359.47M 3.28M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Takeda JPY 1.11T 85.29B Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Xencor USD 82.38M 513K Mar/2026